Naporafenib

Naporafenib (ERAS-254, LXH254) is a small-molecule drug developed by Erasca. The sponsor describes its target as RAF (pan-RAF), which OnCo does not yet have a target page for. The sponsor states: An experimental pan-RAF inhibitor blocking RAF kinase signalling in the MAPK pathway, studied in combination with the MEK inhibitor trametinib in NRAS-mutant melanoma. ClinicalTrials.gov describes the intervention as: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)), in melanoma. The largest, NCT06346067, plans to enrol 78 participants (actual) with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.